Damian Garde from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study - 5 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 5 months ago STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio - 5 months ago The clock is ticking, and Cytokinetics is running out of December - 5 months ago STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease - 5 months ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago BioMarin appeases an activist - 5 months ago STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer - 5 months ago STAT+: 3 trends to watch in biotech in 2024 - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Is it time to worry about Moderna? - 5 months ago A plot to solve the ‘whack-a-mole’ of drug discovery - 5 months ago Tome Biosciences goes public today in another biotech megaround - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 5 months ago Eli Lilly’s latest $1.4 billion deal might come unglued - 5 months ago Why Cerevel Therapeutics has risen 50% in three days without changing anything - 6 months ago Carmot’s chance of beating the odds in the biotech market just ended - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Do GLP-1s have a future treating alcoholism? - 6 months ago STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion - 6 months ago Flagship Pioneering crosses the pond, opens a European front - 6 months ago STAT+: With biotech in a slump, the industry’s job market is upside down - 6 months ago Medtronic isn’t afraid of Wegovy’s potential to disrupt - 6 months ago Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead - 6 months ago STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup - 6 months ago The return of biotech’s “bump factor” amid an economic downturn - 6 months ago How do we know Alzheimer’s drugs ‘work’? - 6 months ago STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward - 6 months ago The apparently strong correlation between biotech stocks and the price of eggs, explained - 6 months ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Eli Lilly tries a rare tactic: competing on price - 6 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - 6 months ago BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge - 6 months ago Your morning biotech news roundup - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis - 7 months ago Gene editing has had a big week in the spotlight. Here’s what’s going on - 7 months ago Sarepta’s disappointing data put the FDA in a difficult spot - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro - 7 months ago The XBI biotech index hit its lowest point since 2018. No one knows what comes next. - 7 months ago Why AstraZeneca’s CEO is accusing British tabloids of ‘fake news’ - 7 months ago STAT+: The future of Biogen: Pragmatism, ‘a few moonshots,’ and no Twinkies - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago What if there’s no market for a CRISPR cure? - 7 months ago As Pfizer slashes revenue projections, Moderna says it “remains comfortable” - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago Cell and gene therapies could be a safer bet than other drugs - 7 months ago With Ozempic, Wall Street moves on from a whole other class of medicines - 7 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: What comes after Wegovy? The quest to eradicate obesity - 5 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: What comes after Wegovy? The quest to eradicate obesity - 5 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - 6 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 5 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 5 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago
6	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: With biotech in a slump, the industry’s job market is upside down - 6 months ago